Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Reports 16-Percent Decline in Q1 Revenues, Narrowed Loss

NEW YORK, May 9 (GenomeWeb News) - Sequenom today reported a 16-percent drop in revenues amidst narrowed losses for the first quarter of 2005.

 

Revenues for the quarter ended March 31 fell to $4.3 million from $5.1 million during the first quarter of 2004. Revenues were "impacted" this quarter by conditions Sequenom granted to new customers that enable it to recognize some revenues later this year.

 

"We believe that our MassArray products continue to gain traction in the clinical research market," with 130 systems installed so far, said acting-CEO and CFO Steve Zaniboni in a statement.

 

Research and development expenses fell to $3.2 million from $5.5 million during the same quarter last year.

 

Sequenom's net loss for the quarter narrowed to $7.4 million, or $.18 per share, from $9.9 million, or $.25 per share, during the year-ago period.

 

As of March 31, Sequenom had $31.4 million in cash, cash equivalents, short-term investments, and restricted cash.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.